European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm
Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis…
September 17, 2019 - 4 minutes
GeNeuro
Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis
An antibody that blocks the action of a hidden viral protein encoded by our genome…
March 12, 2019 - 3 minutes
Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II
GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in…
March 26, 2018 - 2 minutes
This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease
The FDA has awarded Orphan Drug Designation to GeNeuro's antibody for the treatment of a…
February 26, 2018 - 2 minutes
Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis
A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in…
November 1, 2017 - 2 minutes
In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…
May 30, 2017 - 7 minutes
How Biotech is Mastering Multiple Sclerosis: A Review
With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis.…
April 25, 2017 - 7 minutes
Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment
GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company's CFO, who…
September 30, 2016 - 1 minute
First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!
We last wrote about GeNeuro in January, when they announced the launch of an IPO…
April 16, 2016 - 2 minutes
Will there be a New Merck-Serono?
GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought…
December 15, 2014 - 2 minutes
